[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-001", "question": "A 63-year-old man with ischemic cardiomyopathy (LVEF 20%) and NYHA class III symptoms despite guideline-directed therapy presents with increasing fatigue and abdominal swelling. BP is 88/54 mm Hg, HR 78/min, JVP 15 cm with prominent v waves, and there is a holosystolic murmur at the left lower sternal border that increases with inspiration. Echo shows severe functional tricuspid regurgitation with right atrial and RV dilation, TAPSE 1.0 cm, RV fractional area change 25%, PASP 42 mm Hg, and no significant left-sided valvular disease. Coronary anatomy is unchanged from prior and not revascularizable. He is in sinus rhythm and not a heart transplant candidate. After optimization of diuretics, he remains symptomatic. Which management strategy is most appropriate to improve outcomes?", "options": ["Surgical tricuspid valve replacement with bioprosthesis", "Catheter-based edge-to-edge tricuspid valve repair", "Isolated LV assist device implantation", "Upgrade to CRT-D with AV node ablation", "Intensification of neurohormonal blockade with sacubitril/valsartan uptitration"], "answer": "B", "answer_index": 1, "explanation": "In advanced HFrEF with severe secondary TR, RV dysfunction, and prohibitive surgical risk, transcatheter edge-to-edge tricuspid repair is preferred and has evidence for symptomatic and functional improvement versus medical therapy alone. Surgical replacement carries high perioperative mortality with poor RV reserve; isolated LVAD can worsen RV failure; CRT-D and further neurohormonal titration are unlikely to meaningfully reverse severe functional TR at this stage.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let’s break this down:  \n\n- The patient has **ischemic cardiomyopathy with LVEF 20%** and NYHA class III symptoms despite guideline-directed therapy.  \n- Exam and echo show **severe functional tricuspid regurgitation (TR)** with right heart dilation, reduced RV function (TAPSE 1.0 cm, RV FAC 25%), and **only mildly elevated PASP (42 mmHg)**.  \n- He is **not a transplant candidate**, coronary disease not revascularizable, in sinus rhythm.  \n- After diuretic optimization, still symptomatic.  \n- Key point: The TR here is **functional**, likely due to annular dilation from RV/LV failure, not primary valve disease.  \n\n**Option analysis:**  \n- **A (Surgical TV replacement)** – High risk given low LVEF, RV dysfunction, and low BP; isolated TV surgery rarely indicated for functional TR without left-sided surgery.  \n- **B (Catheter-based edge-to-edge repair)** – Less invasive, but in functional TR with severe RV dysfunction, benefit uncertain; may be considered but not clearly shown to improve mortality in advanced biventricular failure.  \n- **C (Isolated LVAD)** – Could worsen TR initially, but in advanced heart failure with low LVEF, LVAD improves forward flow and may reduce secondary TR; however, RV failure risk is high given low TAPSE. Still, in NYHA class III–IV not responding to meds, LVAD is a guideline-supported option to improve outcomes (survival and symptoms).  \n- **D (Upgrade to CRT-D + AV node ablation)** – He is in sinus rhythm, no indication for AV node ablation; QRS width not mentioned, so not clearly indicated.  \n- **E (Sacubitril/valsartan uptitration)** – BP already low (88/54), likely intolerant of further neurohormonal blockade uptitration.  \n\nGiven **ischemic cardiomyopathy, LVEF 20%, NYHA class III despite optimal meds, not transplant candidate**, the most appropriate strategy to improve mortality and symptoms is **advanced heart failure therapy: LVAD** (destination therapy). Isolated LVAD can improve hemodynamics and possibly TR indirectly, and is supported by trials in such patients.  \n\n**The answer is C.**  \n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-002", "question": "A 41-year-old woman presents with progressive exertional dyspnea and chest tightness. She has no smoking history, takes combined oral contraceptives, and has a brother who died suddenly at 32. Exam shows a loud P2 and a systolic murmur that increases with inspiration. ECG shows right axis deviation and incomplete RBBB. Transthoracic echo reveals severe pulmonary hypertension with estimated PASP 80 mm Hg, normal LV, and RV hypertrophy with preserved function. V/Q scan is normal. Right-heart cath shows: RA 6 mm Hg, RV 90/6 mm Hg, PA 88/32 mm Hg (mean 52), PCWP 9 mm Hg, CI 2.1 L/min/m², PVR 10 Wood units. Acute vasoreactivity testing with inhaled nitric oxide reduces mPAP to 42 mm Hg with unchanged CI and PVR 8 Wood units. Genetic testing is pending. What is the most appropriate initial long-term therapy?", "options": ["High-dose amlodipine monotherapy", "Combination therapy with ambrisentan and tadalafil", "Intravenous epoprostenol monotherapy", "Riociguat monotherapy", "Warfarin with target INR 3.0-4.0"], "answer": "B", "answer_index": 1, "explanation": "She has idiopathic or heritable PAH (group 1) with high-risk features and a negative acute vasoreactivity test (insufficient mPAP reduction and no CI improvement), so calcium channel blocker therapy is contraindicated. Current guidelines favor initial oral combination therapy with an endothelin receptor antagonist and a PDE5 inhibitor (e.g., ambrisentan+tadalafil) for WHO FC II-III with preserved RV function; IV epoprostenol is reserved for higher-risk or rapidly progressive disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has severe pulmonary arterial hypertension (PAH) confirmed by right-heart catheterization (mPAP > 20 mmHg, PCWP ≤ 15 mmHg, PVR > 2 WU), with a normal V/Q scan ruling out chronic thromboembolic PH.  \nShe has a family history of sudden death (suggesting possible heritable PAH) and is on oral contraceptives (a risk factor).  \nAcute vasoreactivity testing with inhaled nitric oxide showed a drop in mPAP by ≥10 mmHg to <40 mmHg, but PVR remains elevated (>2 WU) and she did not achieve a full vasoreactive responder criteria (which requires mPAP drop to <40 mmHg with normal/near-normal cardiac output). Therefore, she is not a candidate for high-dose calcium channel blocker therapy.  \n\nInitial long-term therapy for severe PAH (WHO functional class likely III–IV given CI 2.1) should be combination oral therapy (endothelin receptor antagonist + PDE5 inhibitor) unless contraindicated. Ambrisentan + tadalafil is an evidence-based initial combination for such patients.  \n\n- A: Amlodipine monotherapy is inappropriate for non-responders to vasoreactivity testing.  \n- C: IV epoprostenol is reserved for high-risk/severe cases, but initial oral combination is appropriate for many severe patients unless very high risk.  \n- D: Riociguat is used for PAH but not necessarily first-line over ERA+PDE5i in this context; also used for CTEPH.  \n- E: Warfarin is not routinely recommended in PAH without other indications.  \n\nThe answer is B"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-003", "question": "A 27-year-old man presents with a first generalized tonic-clonic seizure. MRI brain with and without contrast is normal. EEG shows rare generalized spike-and-wave discharges at 3-4 Hz with a photoparoxysmal response. Over the next month he has two more generalized tonic-clonic seizures, each preceded by brief myoclonic jerks on awakening. He drinks socially and works as a software engineer. He and his partner plan to conceive in the next year, and he wants to avoid cognitive side effects. Which antiepileptic monotherapy is most appropriate?", "options": ["Valproate", "Levetiracetam", "Carbamazepine", "Lamotrigine", "Topiramate"], "answer": "B", "answer_index": 1, "explanation": "This is juvenile myoclonic epilepsy with generalized tonic-clonic and myoclonic seizures plus characteristic EEG. While valproate is highly effective, its teratogenicity, metabolic effects, and cognitive risks make it less desirable in a young adult planning pregnancy with a partner and with concerns about adverse effects. Levetiracetam is effective for generalized epilepsies, has a favorable cognitive profile, and minimal drug interactions; carbamazepine can worsen generalized seizures, and lamotrigine/topiramate are less predictably effective for myoclonus.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient’s history suggests juvenile myoclonic epilepsy (JME) — generalized tonic-clonic seizures, myoclonic jerks on awakening, normal MRI, EEG with generalized spike-and-wave and photoparoxysmal response.  \n\nFirst-line treatments for JME include valproate, levetiracetam, and lamotrigine, but valproate is most effective. However, the patient plans to conceive in the next year — valproate has high teratogenic risk and should be avoided in men planning conception due to potential sperm effects and fetal risks if the father is taking it.  \n\nLamotrigine is less effective for myoclonic seizures and may even worsen them in some cases. Levetiracetam is effective for JME, has relatively few cognitive side effects compared to topiramate, and is safe for pregnancy planning. Carbamazepine can worsen generalized epilepsies like JME. Topiramate has more cognitive side effects, which the patient wants to avoid.  \n\nThus, levetiracetam balances efficacy in JME, safety for conception, and minimal cognitive impact.  \n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-004", "question": "A 55-year-old woman with a 10-year history of poorly controlled type 2 diabetes presents with episodic confusion, sweating, and palpitations occurring mostly late afternoon. Capillary glucose during an event is 38 mg/dL, resolving with IV dextrose. She takes metformin and basal insulin at night; CGM shows multiple daytime hypoglycemic episodes despite reduction in insulin dose. She denies sulfonylurea use or alcohol. Fasting lab evaluation during supervised 48-hour fast is terminated at plasma glucose 42 mg/dL: insulin 6 μU/mL (normal 2-10), C-peptide 0.1 ng/mL (low), beta-hydroxybutyrate undetectable, and sulfonylurea/meglitinide screen negative. CT of the pancreas is normal. What is the most likely diagnosis?", "options": ["Factitious hypoglycemia from exogenous insulin analog use", "Insulinoma with intermittent secretion", "Non-islet cell tumor hypoglycemia due to IGF-2 secretion", "Autoimmune insulin receptor activating antibody syndrome", "Post-bariatric surgery hyperinsulinemic hypoglycemia"], "answer": "A", "answer_index": 0, "explanation": "Low C-peptide with inappropriately normal insulin at hypoglycemia and absent ketones indicates exogenous insulin, which suppresses endogenous insulin/C-peptide and ketogenesis. Standard insulin immunoassays may underdetect some analogs, yielding low-normal levels; nonetheless, the mismatch of insulin, C-peptide, and ketones supports factitious insulin use rather than insulinoma or IGF-2-mediated hypoglycemia (which would show low insulin/C-peptide but also low ketones via IGF-2 effects).", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient’s presentation shows hypoglycemia with low C-peptide and undetectable beta-hydroxybutyrate despite low glucose, indicating insulin action without endogenous insulin secretion.  \nThe low C-peptide during hypoglycemia rules out insulinoma or endogenous hyperinsulinism.  \nNegative sulfonylurea screen and no history of bariatric surgery help exclude those causes.  \nUndetectable ketones suggest insulin effect is present, but the insulin level is only 6 μU/mL (not elevated), which is inconsistent with insulinoma.  \nThis pattern—hypoglycemia with low C-peptide, low insulin, suppressed ketones—is classic for factitious hypoglycemia from exogenous insulin analog use, because insulin analogs are not detected in standard insulin assays (or may be detected variably), and they suppress endogenous insulin and C-peptide.  \n\n**The answer is A**"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-005", "question": "A 49-year-old man with poorly controlled hypertension and obesity presents with sudden severe dyspnea and pleuritic chest pain. He is tachypneic, diaphoretic, BP 82/54 mm Hg, HR 128/min, SpO2 86% on non-rebreather. JVP is 12 cm, lungs are clear. Bedside echo shows a dilated RV with McConnell sign and septal flattening; there is no pericardial effusion. CTA confirms a massive saddle pulmonary embolism with bilateral lobar clot burden. While preparing for systemic thrombolysis, he becomes pulseless with PEA. After 10 minutes of ACLS with ongoing CPR and no ROSC, what is the most appropriate next step?", "options": ["Administer full-dose systemic alteplase as a bolus during CPR", "Initiate venoarterial extracorporeal membrane oxygenation (VA-ECMO) followed by catheter-directed thrombectomy", "Administer half-dose systemic alteplase and continue CPR for at least 30 minutes", "Terminate resuscitation efforts due to poor prognosis", "Perform emergency surgical pulmonary embolectomy without ECMO"], "answer": "B", "answer_index": 1, "explanation": "In massive PE with refractory cardiac arrest and no ROSC after high-quality ACLS, VA-ECMO can provide immediate circulatory support and oxygenation, serving as a bridge to definitive reperfusion (catheter-directed or surgical embolectomy). Evidence and expert consensus increasingly support ECMO plus mechanical thrombectomy over late systemic lysis in this setting; halving the alteplase dose or surgical embolectomy without circulatory support are less effective and more dangerous during ongoing arrest.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient is in cardiac arrest from a massive PE with confirmed saddle embolism and PEA after 10 minutes of ACLS without ROSC.  \nIn this scenario, ongoing CPR with persistent PEA from massive PE may still be salvageable if circulation can be restored rapidly.  \nSystemic thrombolysis during CPR is recommended (Class IIa in guidelines), but full-dose bolus carries bleeding risk, and half-dose may be less effective.  \nHowever, the most definitive approach in a patient who remains in arrest despite CPR and who already has a confirmed massive PE is to establish mechanical circulatory support with VA-ECMO (to restore perfusion) followed by catheter-based or surgical embolectomy.  \nVA-ECMO can provide oxygenation and circulation while the clot is removed, and this strategy is increasingly used in refractory cardiac arrest from massive PE (PE-ECMO).  \nSurgical embolectomy without ECMO in ongoing arrest is very high risk and less likely to succeed without prior circulatory support.  \n\nThe best option here is initiating VA-ECMO followed by catheter-directed thrombectomy.  \n\nThe answer is B"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-006", "question": "A 38-year-old woman presents with progressive proximal muscle weakness over 6 weeks, difficulty climbing stairs, and new-onset dry cough. Exam shows 4/5 strength in hip flexors and shoulder abductors, Gottron papules over MCP joints, and a faint \"mechanic's hands\" rash. CK is 700 IU/L (mildly elevated). High-resolution CT shows bilateral peripheral ground-glass opacities and traction bronchiectasis in lower lobes. Pulmonary function tests show FVC 60% predicted, DLCO 35% predicted, and an FVC/DLCO ratio >1.6. ANA is positive 1:320 speckled. Which specific autoantibody, if present, would indicate the highest risk of rapidly progressive interstitial lung disease requiring aggressive early immunosuppression?", "options": ["Anti-Jo-1 (histidyl-tRNA synthetase)", "Anti-Mi-2", "Anti-MDA5", "Anti-SRP", "Anti-TIF1-γ"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 dermatomyositis is characteristically associated with rapidly progressive, often fatal ILD, even with only mild myositis or CK elevation, and warrants early aggressive combination immunosuppression. Anti-Jo-1 also associates with ILD but usually more indolent; anti-Mi-2 is linked to classic dermatomyositis with good prognosis; anti-SRP to necrotizing myopathy; anti-TIF1-γ to malignancy-associated dermatomyositis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has dermatomyositis with characteristic skin findings (Gottron papules, mechanic’s hands) and interstitial lung disease (ILD) with a pattern suggesting nonspecific interstitial pneumonia or organizing pneumonia on HRCT.  \nThe FVC/DLCO ratio >1.6 indicates disproportionate reduction in gas exchange relative to lung volumes, often seen in connective tissue disease–associated ILD.  \n\nAmong the listed autoantibodies, **anti-MDA5** is strongly associated with dermatomyositis and a high risk of rapidly progressive ILD, which can be fatal if not treated aggressively early on. Anti-MDA5 is also linked with clinically amyopathic dermatomyositis and poor prognosis in ILD.  \n\nThe answer is C.  \n\nThe answer is C"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-007", "question": "A 72-year-old man with long-standing COPD (FEV1 35% predicted), chronic hypercapnia, and recent admission for an acute exacerbation requiring noninvasive ventilation is evaluated 3 weeks after discharge. He continues to have daytime somnolence and morning headaches despite resolution of wheeze and normalization of oxygenation on 2 L/min nasal cannula. ABG on his usual oxygen shows pH 7.37, PaCO2 58 mm Hg, PaO2 70 mm Hg, HCO3- 33 mEq/L. Overnight oximetry reveals sustained hypoventilation with episodic desaturations but no significant obstructive apneas. He is adherent to inhaled therapy and pulmonary rehab. What is the most appropriate next step in chronic management to improve mortality?", "options": ["Increase long-term oxygen therapy to maintain PaO2 >80 mm Hg", "Start nocturnal noninvasive ventilation with targeted normalization of PaCO2", "Add chronic low-dose oral prednisone", "Begin acetazolamide at night to stimulate ventilation", "Switch to high-flow nasal cannula at home during sleep"], "answer": "B", "answer_index": 1, "explanation": "In stable COPD with chronic hypercapnic respiratory failure, particularly after a hypercapnic exacerbation, nocturnal noninvasive ventilation targeting PaCO2 reduction reduces mortality and hospitalizations. Increasing oxygen can worsen hypercapnia; chronic steroids confer harm; acetazolamide has limited long-term data; home high-flow therapy improves comfort but lacks robust mortality benefit compared with NIV in this phenotype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has severe COPD with chronic hypercapnia and persistent symptoms of hypercapnia (daytime somnolence, morning headaches) despite optimal medical therapy and recent acute exacerbation requiring NIV.  \nOvernight oximetry shows sustained hypoventilation without significant obstructive sleep apnea, indicating obesity hypoventilation is not the primary issue, but rather chronic hypercapnic respiratory failure due to COPD.  \n\nIn COPD patients with chronic hypercapnia and a recent hospitalization requiring NIV, long-term nocturnal noninvasive ventilation with a goal of reducing hypercapnia (not necessarily normalizing PaCO₂) has been shown in recent trials (e.g., HOT-HMV trial) to reduce mortality and readmissions when targeted to significantly lower PaCO₂.  \n\nIncreasing oxygen alone risks worsening hypercapnia without treating the hypoventilation.  \nOral steroids are not indicated for chronic management due to side effects.  \nAcetazolamide is not first-line in this setting and does not have mortality benefit.  \nHigh-flow nasal cannula may improve oxygenation and comfort but is not proven to reduce mortality in hypercapnic COPD.  \n\nThe most appropriate next step for mortality benefit is **nocturnal NIV targeted to lower PaCO₂**.  \n\nThe answer is B"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-008", "question": "A 59-year-old man with a history of MI and paroxysmal atrial fibrillation presents with acute-onset right eye visual loss described as a \"curtain\" descending over 10 minutes, now partially improved. Exam reveals a right relative afferent pupillary defect and patchy visual field deficit; neurologic exam is otherwise normal. He takes apixaban 5 mg twice daily, metoprolol, and atorvastatin, and reports strict adherence. BP is 130/72 mm Hg. MRI brain with DWI is normal; MRA head/neck shows no large-vessel occlusion or significant carotid stenosis. Fundoscopic exam shows retinal whitening in the inferior arcade consistent with branch retinal artery occlusion (BRAO). Which management strategy is most appropriate regarding his antithrombotic regimen?", "options": ["Continue apixaban and add aspirin 81 mg daily indefinitely", "Switch apixaban to warfarin with target INR 2.5-3.5", "Continue apixaban at the same dose without change", "Increase apixaban dose to 10 mg twice daily for 1 month, then 5 mg twice daily", "Discontinue anticoagulation and use dual antiplatelet therapy for 90 days"], "answer": "C", "answer_index": 2, "explanation": "BRAO in an anticoagulated AF patient is treated as a small ischemic stroke; however, there is no high-level evidence that switching DOACs, adding chronic antiplatelet therapy, or using higher-dose anticoagulation improves outcomes over continuing appropriate-dose DOAC once adherence and dosing are confirmed. Adding aspirin increases bleeding risk without proven benefit; warfarin or dual antiplatelets are not superior for AF-related events when DOAC therapy is adequate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": null, "model_outputs": ""}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-009", "question": "A 46-year-old man presents with sudden severe tearing chest pain radiating to the back. BP is 210/110 mm Hg in both arms, HR 112/min. CT angiography shows an acute Stanford type B aortic dissection starting distal to the left subclavian artery and extending to the infrarenal aorta with involvement of the origin of the left renal artery, but no signs of rupture or pericardial effusion. The left kidney is perfused via a narrowed true lumen; creatinine is 1.4 mg/dL (baseline 1.0). There is no limb ischemia, mesenteric ischemia, or refractory pain after initial IV beta-blocker and vasodilator therapy, and BP is controlled to 115/70 mm Hg. Which management strategy is most appropriate now?", "options": ["Immediate thoracic endovascular aortic repair (TEVAR) to prevent late aneurysmal degeneration", "Open surgical repair of the descending thoracic aorta due to renal artery involvement", "Strict medical therapy with anti-impulse control and serial imaging", "Prophylactic left renal artery stenting plus medical therapy", "Fenestration and true lumen expansion with balloon angioplasty"], "answer": "C", "answer_index": 2, "explanation": "Uncomplicated type B aortic dissection without rupture, malperfusion, refractory pain, or uncontrolled hypertension is managed initially with aggressive medical therapy and surveillance. Renal artery involvement without clinical malperfusion or progressive renal dysfunction does not mandate immediate TEVAR or intervention; endovascular repair is reserved for complicated cases or aneurysmal progression on follow-up imaging.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has an uncomplicated Stanford type B aortic dissection (no rupture, malperfusion, refractory pain/hypertension, or other high-risk features). Renal artery involvement with mild creatinine elevation and adequate perfusion via the true lumen does not itself constitute complicated dissection requiring intervention.  \n\nCurrent guidelines recommend initial medical management with anti-impulse therapy and close monitoring for uncomplicated type B dissections. TEVAR is not indicated immediately solely to prevent late aneurysmal degeneration, and renal artery stenting or fenestration is not warranted without evidence of significant malperfusion.  \n\n**The answer is C**"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-010", "question": "A 24-year-old man presents to the ED after being found confused and agitated. He reports taking an unknown \"research chemical\" for recreation. Vitals: T 40.1°C, HR 146/min, BP 178/104 mm Hg, RR 28/min, SpO2 96% RA. Exam shows mydriasis, diaphoresis, severe agitation with tremor, hyperreflexia, and inducible clonus, but no muscle rigidity. He is not taking prescription drugs and denies MAOI or SSRI use. Labs: Na 138, K 4.1, creatinine 1.0, CK 200 IU/L, normal LFTs. UDS is positive only for amphetamines. Despite high-dose benzodiazepines he remains agitated and hyperthermic. Which is the most appropriate next pharmacologic intervention?", "options": ["Intravenous dantrolene", "Intravenous cyproheptadine via crushed tablets", "Intravenous nitroprusside for blood pressure control alone", "Intravenous dexmedetomidine infusion", "Intravenous bromocriptine"], "answer": "D", "answer_index": 3, "explanation": "This is severe sympathomimetic (likely synthetic stimulant) toxicity with hyperthermia and agitation; there is hyperreflexia but the overall picture and isolated amphetamine screen favor stimulant rather than true serotonin syndrome. When benzodiazepines are insufficient, dexmedetomidine provides sympatholysis and sedation without worsening hyperthermia or respiratory drive as much as deep barbiturate or propofol sedation. Cyproheptadine and dantrolene target serotonin syndrome and NMS, respectively; bromocriptine is used in NMS and would exacerbate sympathomimetic effects.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has a presentation consistent with serotonin syndrome (inducible clonus, agitation, hyperthermia, hyperreflexia, autonomic instability, with an amphetamine positive UDS — amphetamines increase serotonin release and inhibit reuptake).  \nHe has failed high-dose benzodiazepines and remains agitated and hyperthermic.  \nThe next recommended pharmacologic intervention for serotonin syndrome refractory to benzodiazepines is **cyproheptadine**, a serotonin antagonist, given orally or via NG tube (IV formulation is not commercially available, but tablets can be crushed and administered via NG in practice).  \n\n- Dantrolene (A) is for malignant hyperthermia (which involves muscle rigidity, not typically present here).  \n- Nitroprusside (C) only addresses BP, not the underlying serotonin syndrome.  \n- Dexmedetomidine (D) may help agitation but is not a first-line serotonin antagonist.  \n- Bromocriptine (E) is for neuroleptic malignant syndrome, and could worsen serotonin syndrome.  \n\nThe best choice is **cyproheptadine**.  \n\n**The answer is B**"}]